Theranostics in prostaatkanker

Translated title of the contribution: Theranostics in prostate cancer

Bastiaan M. Privé*, Constantijn H.J. Muselaers, Steffie M.B. Peters, Bart Timmermans, Harm Westdorp, Mira D. Franken, André N. Vis, Marcel J.R. Janssen, Daniela E. Oprea-Lager, James Nagarajah

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Downloads (Pure)


177Lu-PSMA is a novel therapy in patients with metastatic castration-resistant prostate carcinoma (mCRPC). The radiolabeled drug is administered intravenously, usually in 4–6 cycles, in which β‑radiation induces intracellular DNA damage and cell death of PSMA-expressing prostate cancer cells. The γ‑decay of the radionuclide can be used for imaging and dosimetry. An international phase III study showed that end stage mCRPC patients that received 177Lu-PSMA had a survival benefit (15.3 vs. 11.3 months; p < 0.001). Moreover, several studies suggest that ~25% of these heavily pre-treated patients respond better and likely have a longer survival benefit. The most important side effects are: grade I–II fatigue (~40%) and xerostomia (~40%), which are mostly transient. Grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) was seen in ~8% of patients. Recently, the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the drug for patients with end stage prostate cancer. Currently, there are several studies investigating if patients in an earlier stage of the disease, metastatic hormone-sensitive or hormone-naïf, can also benefit from therapy with 177Lu-PSMA.

Translated title of the contributionTheranostics in prostate cancer
Original languageDutch
Pages (from-to)63-72
Number of pages10
JournalTijdschrift voor Urologie
Issue number2-3
Publication statusPublished - 28 Feb 2024

Bibliographical note

Publisher Copyright: © The Author(s) 2024.


Dive into the research topics of 'Theranostics in prostate cancer'. Together they form a unique fingerprint.

Cite this